The application of emerging technologies in genomics and proteomics to drug development

Journal of Pharmacy Practice and Research

Volumn 33, Issue 1, 2003, Pages 7-11

  Mahler, Stephen M ^b   Chin, David Y ^b   Van Dyk, Derek D ^a  

^a MACQUARIE UNIVERSITY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; ECOSYSTEM; GENOMICS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICAL PRACTICE; PHARMACOGENOMICS; PHARMACY; PROTEOMICS; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 0037358342     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jppr20033317     Document Type: Review

References (22)

1. Bailey D, Zanders E, Dean P. The end of the beginning for genomic medicine. Nature Biotechnology 2001; 19: 207-9.
2. Jimenez-Sanchez G, Childs B, Valle D. Human disease genes. Nature 2001; 409: 853-5.
3. Liang F. Gene index analysis of the human genome estimated approximately 120,000 genes. Nature Genetics 2000; 25: 239-40.
4. Bork P, Copley R. Filling the gaps. Nature 2001; 409: 818-20.
5. Baltimore D. Our genome unveiled. Nature 2001; 409: 814-16.
6. Bimey E, Bateman A, Clamp ME, Hubbard TJ. Mining the draft human genome. Nature 2001; 409: 827-8.
7. Stoneking M. From the evolutionary past. Nature 2001; 409: 821-2.
8. Chakravarti A. To a future of genetic medicine. Nature 2001; 409: 822-3.
9. Gould Rothberg B.E. Mapping a role for SNPs in drug development. Nature Biotechnology 2001; 19: 209-11.
10. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
11. Fletcher L. Curagen sets precedent in post genomics era. Nature Biotechnology 2001; 19: 186-7.
12. Sorek R, Amitai M. Piecing together the significance of splicing era. Nature Biotechnology 2001; 19: 196.
13. Rubin GM. Comparing species. Nature 2001; 409: 820-1.
14. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
15. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res 1999; 16: 342-9.
16. Huber LA, Pasquali C, Gagescu R, Zuk A, Gruenber GJ, Matlin KS. Endosomal fractions from viral K-ras-transformed MDCK cells reveal transformation specific changes on two-dimensional gel maps. Electrophoresis 1996; 17: 1734-40.
17. Molloy MP, Herbert BR, Walsh BJ, Tyler MI, Traini M, Sanchez JC, et al. Extraction of membrane proteins by differential solubilization for separation using two-dimensional gel electrophoresis. Electrophoresis 1998; 19: 837-44.
18. Herbert B, Righetti PG. A turning point in proteome analysis: Sample prefractionation via multicompartment electrolyzers with isoelectric membranes. Electrophoresis 2000; 21: 3639-48.
19. Zuo X, Echan L, Hembach P, Tang HY, Speicher KD, Santoli D, et al. Towards global analysis of mammalian proteomes using sample prefractionation prior to narrow pH range two-dimensional gels and using one-dimensional gels for insoluble and large proteins. Electrophoresis 2001; 22: 1603-15.
20. Corthals GL, Molloy MP, Herbert BR, Williams KL, Gooley AA. Prefractionation of protein samples prior to two-dimensional electrophoresis. Electrophoresis 1997; 18: 317-23.
21. Moore AV, Jorgensen JW. Comprehensive three-dimensional separation of peptides using size exclusion chromatography/reversed phase liquid chromatography/optically gated capillary zone electrophoresis. Analytical Chemistry 1995; 67: 3448-55.
22. Lee H, Griffin TJ, Gygi SP, Rist B, Aebersold R. Development of a multiplexed microcapillary liquid chromatography system for high-throughput proteome analysis. Analytical Chemistry 2002; 74: 4353-60.